GHRP-2 + LUV TES + MGF + Ipamorelin

A four-component research blend of three short synthetic peptides and a 24-residue E-peptide fragment corresponding to a splice variant of the IGF-1 gene, characterized by sequence, molecular formula, and structural class.

Molecular Profile

Type
Peptide blend

Components

GHRP-2

Molecular formula
C45H55N9O6
Molecular weight
817.97 g/mol
CAS number
158861-67-7
Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2

LUV TES

Molecular formula
C221H366N72O67S
Molecular weight
5135.89 g/mol
CAS number
218949-48-5

MGF

Molecular formula
C121H200N42O39
Molecular weight
2888.16 g/mol
Sequence
YQPPSTNKNTKSQRRKGSTFEEHK

Ipamorelin

Molecular formula
C38H49N9O5
Molecular weight
711.87 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2

Mechanism & Target Class

GHRP-2 and Ipamorelin are short synthetic peptides built largely from non-standard and D-configured residues. GHRP-2 is a hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) and Ipamorelin is a C-terminally amidated pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2); both carry a class of small peptides that engage a G-protein-coupled receptor, and their D-amino-acid content and C-terminal amidation confer protease resistance. LUV TES is a large synthetic peptide whose sequence is based on a 44-residue hypothalamic peptide; a hexenoyl modification at the N-terminus distinguishes it structurally from the native sequence and stabilizes the molecule. MGF is a 24-residue C-terminal E-peptide fragment whose sequence (YQPPSTNKNTKSQRRKGSTFEEHK) corresponds to a mechanical-stress-induced splice variant of the IGF-1 gene (IGF-1Ec); its primary structure is distinct from that of full-length IGF-1.

Storage & Handling

Lyophilized
GHRP-2, MGF, Ipamorelin: -20°C to -80°C. LUV TES: 2–8°C.
Handling
Avoid repeated freeze-thaw cycles for GHRP-2, MGF, and Ipamorelin. Protect LUV TES from light.

References (18)

  1. Reviews

    1

    Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. (2020). JCSM Rapid Communications

    DOI: 10.1002/rco2.9

  2. 2

    Sinha DK, Balasubramanian A, Rivera-Vega MR, et al. (2020). Translational Andrology and Urology

    DOI: 10.21037/tau.2019.11.01PubMed 32257853

  3. 3

    Mosińska P, Zatorski H, Storr M. (2017). Journal of Neuroendocrinology

    DOI: 10.1111/jne.12457PubMed 28064448

  4. 4

    Goldspink G. (2010). Endocrinology

    DOI: 10.1210/en.2009-1106PubMed 20019125

  5. Primary research

    5

    Beck IT, Sweeny WB, McCarter MD, et al. (2014). International Journal of Colorectal Disease

    DOI: 10.1007/s00384-014-2030-8PubMed 25331030NCT00672074

  6. 6

    Mamputu JC, Falutz J, Potvin D, et al. (2012). Clinical Infectious Diseases

    DOI: 10.1093/cid/cis250PubMed 22495074

  7. 7

    Falutz J, Mamputu JC, Potvin D, et al. (2010). Journal of Clinical Endocrinology & Metabolism

    DOI: 10.1210/jc.2010-0272PubMed 20554713

  8. 8

    Falutz J, Allas S, Blot K, et al. (2007). New England Journal of Medicine

    DOI: 10.1056/NEJMoa072375PubMed 18057338NCT00123253

  9. 9

    Pihoker C, Pescovitz OH, Rogol AD, et al. (1995). Journal of Clinical Endocrinology & Metabolism

    DOI: 10.1210/jcem.80.10.7559885PubMed 7559885

  10. 10

    Tauber M, Pihoker C, Rogol AD, et al. (1993). Journal of Clinical Endocrinology & Metabolism

    DOI: 10.1210/jcem.76.5.8496311PubMed 8496311

  11. 11

    Zhang B, Liu Z, Li X, et al. (2023). International Journal of Molecular Medicine

    DOI: 10.3892/ijmm.2023.5256PubMed 37194631

  12. 12

    Venkova K, Mann W, Nelson R, et al. (2009). Journal of Pharmacology and Experimental Therapeutics

    DOI: 10.1124/jpet.108.145334PubMed 19168603

  13. 13

    Dluzniewska J, Sarnowska A, Lee J, et al. (2005). FASEB Journal

    DOI: 10.1096/fj.05-3786fjePubMed 16144956

  14. 14

    Laferrère B, Bressler P, David D, et al. (2002). Journal of Clinical Endocrinology & Metabolism

    DOI: 10.1210/jc.2001-010542PubMed 11994336

  15. 15

    Yang SY, Goldspink G. (2002). FEBS Letters

    DOI: 10.1016/S0014-5793(02)02913-6PubMed 12103360

  16. 16

    Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Lancet HIV

    DOI: 10.1016/S2352-3018(19)30338-8PubMed 31611038NCT02196831

  17. 17

    Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. (2011). Mechanisms of Ageing and Development

    DOI: 10.1016/j.mad.2011.02.007PubMed 21354439

  18. 18

    Raun K, Hansen BS, Johansen NL, et al. (1998). European Journal of Endocrinology

    DOI: 10.1530/eje.0.1390552PubMed 9849822